A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety
Part of paid clinical trials in Columbus, Ohio.
- Sponsor
- Ohio State University
- Study ID
- NCT06820723
- Phase
- PHASE2
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 21 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- CYB003 — DRUGsynthetic, deuterated isotopomer of psilocin
- Placebo — DRUGPlacebo orange drink solution
Study Details
The goal of this study is to learn how psychedelics may help symptoms of depression and anxiety. Participants with major depressive disorder experiencing symptoms of depression and anxiety will receive one dose of either a drug related to psilocybin or a placebo. Assessments include interviews, self-report questionnaires, EEG and fMRI to measure symptoms and brain function.
Key Dates
- First listed
- Feb 11, 2025
- Start date
- Aug 1, 2026
- Status verified
- Jul 2026
- Primary completion
- Sep 30, 2028
- Completion
- Nov 30, 2028
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- OTHER
Arms
- Experimental: CYB003Participants will receive one dose of CYB003
- Placebo Comparator: PlaceboParticipants will receive one dose of placebo
Primary Outcome Measure
Changes in parameter estimate of regional brain activity measured by fMRI after one dose of CYB003 in participants with MDD and anxiety [ Time Frame: Between Baseline and Time point 24 hours and 21 days post-Investigational Product or placebo ]
Central Contacts
- Anne-Marie Duchemin6142935517
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| The Ohio State University Department of Psychiatry | Columbus | Ohio | 43210 |
Find similar trials in Columbus, OH
By condition
By specialty
By research site
Related Studies
- Mechanisms of Rumination Change in Adolescent DepressionRecruiting · Ohio State University · Columbus, Ohio
- Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)PHASE4 · Recruiting · University of Cincinnati · Cincinnati, Ohio
- Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)PHASE4 · Recruiting · University of Cincinnati · Cincinnati, Ohio
- Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)PHASE4 · Recruiting · University of Cincinnati · Cincinnati, Ohio